Effect of hemodialysis on the pharmacokinetics of 19-nor-1α,25- dihydroxyvitamin D2

American Journal of Kidney Diseases

Volumn 32, Issue 2 SUPPL. 2, 1998, Pages

  Cato III, A ^a   Cady, W W ^a   Soltanek, C ^a   Qasawa, B ^a   Chang, M ^a   Stoll, R ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

19 nor; Hemodialysis; Paricalcitol; Pharmacokinetics

Indexed keywords

ERGOCALCIFEROL DERIVATIVE; PARICALCITOL; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MALE; SECONDARY HYPERPARATHYROIDISM; VITAMIN D METABOLISM;

EID: 0031736270     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.1998.v32.pm9808144     Document Type: Article

References (11)